Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06346509 · ClinicalTrials.gov registry record · Phase 1
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants
A Phase 1 study of Healthy Adult Participants, sponsored by Portal Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT06346509: Recruiting Phase 1 study of Healthy Adult Participants, sponsored by Portal Therapeutics.
NCT06346509 is a Phase 1 study of Healthy Adult Participants that is actively recruiting participants, run by Portal Therapeutics. The registered enrollment target is 108 participants, above the 53-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (104% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06346509, a Phase 1 study of Healthy Adult Participants, is actively recruiting participants, sponsored by Portal Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PORT-77
Study Locations (1)
Arizona
- Celerion - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2025-08-29 |
| Phase | Phase 1 |
What NCT06346509 shows while recruiting
NCT06346509 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (104% higher).
The record links to 1 condition, with Healthy Adult Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06346509 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06346509 about?
NCT06346509 is a clinical study titled "Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants". A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.
What is the current status of trial NCT06346509?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-04-08. Estimated completion is 2025-08-29.
What conditions does trial NCT06346509 study?
This clinical trial studies the following conditions: Healthy Adult Participants.
What interventions are being tested in trial NCT06346509?
The interventions under investigation include: Placebo (DRUG), PORT-77 (DRUG).
Who is sponsoring clinical trial NCT06346509?
This trial is sponsored by Portal Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06346509 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11
RECRUITING · Phase 1
-
A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
COMPLETED · Phase 1
-
Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI